[Retracted] Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment

<div>KEGG, Hallmark, and GO pathway enrichment analyses of patient 1. (a) KEGG, (b) Hallmark, and (c) GO.</div>

Computational and Mathematical Methods in Medicine

fig6

Figure 6

Figure 6: [Retracted] Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment 

Figure 6 | [Retracted] Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment 